Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
AssigneesBiogen Idec MA Inc., Emory University
InventorsJeffrey L. Browning, Maryann Puglielli, Rafi Ahmed
Life of this patent
Estimating the term…
Abstract
This invention provides methods of inducing an antiviral response in an individual comprising administering to the individual an effective amount of a LT-B blocking agent and a pharmaceutically acceptable carrier. In particular this invention provides methods for treating viral-induced systemic shock and respiratory distress.
Claims28
A method of inducing an antiviral response or treating a viral infection in an individual suffering from viral-induced systemic shock mediated by CD8 T cells and/or viral-induced pulmonary distress mediated by CD8 T cells, comprising administering to the individual an effective amount of a pharmaceutical composition comprising a lymphotoxin-beta (LT-beta) or lymphotoxin-beta receptor (LT-beta-R) blocking agent selected from the group consisting of an antibody directed against LT-beta, a soluble LT-beta-R, an antibody directed against LT-beta-R, and an antibody directed against surface LT ligand, and a pharmaceutically acceptable carrier, such that an antiviral response is induced or viral infection treatment occurs.
A method of treating viral-induced systemic shock mediated by CD8 T cells in an individual comprising administering to the individual an effective amount of a pharmaceutical composition comprising a lymphotoxin-beta (LT-beta) or lymphotoxin-beta receptor (LT-beta-R) blocking agent selected from the group consisting of a an antibody directed against LT-beta, a soluble LT-beta-R, an antibody directed against LT-beta-R, and an antibody directed against surface LT ligand, and a pharmaceutically acceptable carrier, such that viral-induced systemic shock is treated.
A method of treating viral-induced pulmonary distress mediated by CD8 T cells in an individual comprising administering to the individual an effective amount of a pharmaceutical composition comprising a lymphotoxin-beta (LT-beta) or lymphotoxin-beta receptor (LT-beta-R) blocking agent selected from the group consisting of an antibody directed against LT-beta, a soluble LT-beta-R, an antibody directed against LT-beta-R, and an antibody directed against surface LT ligand, and a pharmaceutically acceptable carrier, such that viral-induced pulmonary distress is treated.
A method of inducing an antiviral response in a human suffering from viral-induced systemic shock mediated by CD8 T cells and/or viral-induced pulmonary distress mediated by CD8 T cells, comprising administering to the human a pharmaceutical composition comprising a polypeptide that comprises a soluble ligand binding domain of human LT-beta-R fused to a human IgG Fc domain and a pharmaceutically acceptable carrier, such that an antiviral response is induced.
A method of inducing an antiviral response or treating viral infection in an individual infected with Sin Nombre Virus (SNV) who is suffering from viral-induced pulmonary distress, comprising administering to the individual an effective amount of a pharmaceutical composition comprising an LT-beta blocking agent comprising either an antibody directed against LT-beta or an antibody directed against surface LT ligand, and a pharmaceutically acceptable carrier, such that an antiviral response is induced or viral infection treatment occurs.
A method of inducing an antiviral response or treating viral infection in an individual infected with Sin Nombre Virus (SNV) who is suffering from viral-induced pulmonary distress, comprising administering to the individual an effective amount of a pharmaceutical composition comprising a soluble LT-beta-R, and a pharmaceutically acceptable carrier, such that an antiviral response is induced or viral infection treatment occurs.
A method of treating a viral infection in an individual infected with Sin Nombre Virus (SNV) who is suffering from viral-induced systemic shock, comprising administering to the individual an effective amount of a pharmaceutical composition comprising a soluble LT-beta-R, and a pharmaceutically acceptable carrier, such that viral infection treatment occurs.
Dependencies are inferred from the claim text.